Drug intelligence / Profile preview

Glucostrim

Development stage: Unknown
Lead developer: AXM Pharma
Administration: Oral

Overview

**Glucostrim** is an oral proprietary traditional Chinese medicine multi-herb capsule formulation marketed in China as Qiyao Xiaoke Capsule for glycemic disorders. AXM Pharma announced Chinese regulatory approval of Glucostrim in 2005 as an antidiabetic capsule product. Published preclinical and clinical reports under the Qiyao Xiaoke Capsule name have evaluated it in impaired glucose tolerance, type 2 diabetes, and diabetic nephropathy. The exact molecular composition and direct pharmacologic targets were not established in the public sources reviewed; reported activity is framed broadly as improving insulin-related glucose and lipid metabolism.

Brand names: GlucostrimQiyao
Other names: Glucostrim Anti-diabetes CapsulesQXCQiyao Xiaoke CapsuleQiyao Xiaoke Capsules芪药消渴胶囊

Beyond the preview

Go deeper on Glucostrim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucostrim.

Explore the full profile